Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Bioscience research is undergoing a wave of automation and digitization, turning a manual, laborious practice into a true industry.

Why it matters: Biotechnology promises to revolutionize everything from medicine to energy, but for that to happen, the field needs to move out of the traditional lab and into something resembling a foundry. The growth of robotics and cloud-based remote research can help make that happen.

What's happening: In a report published last week, the design and engineering firm Arup made the case that the future of scientific labs will increasingly be automated and digitized, allowing researchers to carry out experiments remotely and scale up their work faster.

  • "Digitization is changing all of our lives, and it's also changing how we do science," said Jennifer DiMambro, Arup's science and business leader for the Americas, in an online event for the report. "We're moving away from designing labs for people to designing them for the tools we use."

How it works: That means labs where experiments can be automated — think robot arms moving vials en masse, rather than overworked graduate students pipetting by hand.

  • Smart facilities can track everything done in a lab, automating data collection that in the past might have been kept on pad and paper and allowing researchers to maximize workflow.
  • Virtual remote labs can be accessed via the cloud, providing on-demand services for sequencing DNA, carrying out reactions and other experiments that can be quickly spun up according to a researcher's needs.
  • "We now have customers who can leverage robots to do a thousand experiments at once that in the past would have been done manually," says Saji Wickramasekara, the CEO of the cloud-based informatics platform Benchling. "You can get far more scale."

Of note: Benchling, which helps life science researchers remotely track and share data, has seen a 35% increase in platform use from customers working on COVID-19.

  • "COVID-19 has really been a forcing function to put the gas pedal down on change and modernize this field," says Wickramasekara.

Zoom in: Speed and industrialization in the lab are particularly vital for developing a COVID-19 vaccine in record time.

  • Ginkgo Bioworks, a Boston-based synthetic biology startup that writes more DNA than any other firm in the world, has lent its platform infrastructure to Moderna to optimize the manufacturing of key ingredients for that company's mRNA vaccine.
  • Ginkgo invested $400 million over the past five years to build a 100,000-square-foot automated bioengineering facility that more closely resembles a biological factory than a traditional lab.

Context: Ginkgo Bioworks, which is now valued at more than $4 billion, represents the cutting edge of biotech industrialization.

  • Rather than producing final products itself, Ginkgo designs and engineers custom-made microbes for customers ranging from fragrances to food flavors to pharmaceuticals.
  • "Our role is helping to improve the manufacturing process," says Jason Kelly, Ginkgo's CEO. "That means faster vaccine development, faster drug development, faster everything."
  • He sees Ginkgo as the Amazon Web Services of the biotechnology field, providing the backstage infrastructure for R&D and engineering. Just as tech startups can quickly outsource their cloud computing needs to a provider like AWS — which lets them grow faster since they don't need to build out their own server farms — Kelly says Ginkgo "wants other people to use us to build their biological apps."
  • The result is what Kelly calls a "general-purpose data center," but for biology. "That is how lab work is going to happen in the future."

What's next: On Tuesday, the Department of Defense announced it would award $87.5 million — which will be matched by more than $180 million in non-federal funding — to establish a manufacturing innovation institute called BioMADE at the University of Minnesota.

  • BioMADE aims to "bridge the gap between lab-scale research and at-scale manufacturing," Douglas Friedman, the CEO of BioMADE, said in a statement.

The bottom line: If the 21st century really is going to be the "age of biology," as some experts have predicted, the field needs to undergo its own version of the Industrial Revolution.

Go deeper

Long COVID leaves patients and researchers in a maze of questions

Illustration: Annelise Capossela/Axios

Millions of COVID-19 survivors worldwide — even those who had mild illness — are reporting long-term symptoms months later, including brain fog, persistent exhaustion, and lung, heart or kidney damage.

Why it matters: For too long, these long-haulers, as they call themselves, have not been taken seriously enough by providers and researchers, some doctors tell Axios, adding that there's an urgent need for dedicated research in order to treat patients with lingering symptoms.

Updated 7 hours ago - Politics & Policy

Omicron dashboard

Illustration: Aïda Amer/Axios

  1. Health: FDA OKs antiviral drug remdesivir for non-hospitalized COVID patients — Walensky: CDC language "pivoting" on "fully vaccinated" — Pfizer and Moderna boosters overwhelmingly prevent Omicron hospitalizations, CDC finds.
  2. Vaccines: The case for Operation Warp Speed 2.0 — Teens and adults missed 37 million vaccinations during COVID — Team USA 100% vaccinated against COVID ahead of Beijing Olympics — Kids' COVID vaccination rates are particularly low in rural America — Annual COVID vaccine preferable to boosters, says Pfizer CEO.
  3. Politics: Arizona governor sues Biden administration over COVID funds tied to mandates — Biden concedes U.S. should have done more testing — Arizona says it "will not be intimidated" by Biden on anti-mask school policies.
  4. World: American Airlines flight to London forced to turn around over mask dispute — WHO: COVID health emergency could end this year — Greece imposes vaccine mandate for people 60 and older — Austria approves COVID vaccine mandate for adults — Beijing officials urge COVID-19 "emergency mode" before Winter Olympics.
  5. Variant tracker
Jan 29, 2021 - World

The global line for coronavirus vaccines stretches back to 2023

Illustration: Eniola Odetunde/Axios

There’s a wild scramble at the front of the line for COVID-19 vaccines, with the EU discussing export bans and legal action to ensure its supply speeds up in the coming months.

The flipside: The back of the line likely stretches to 2023 and beyond. Almost no low-income countries have managed to begin distribution in earnest, and total vaccinations in all of continental sub-Saharan Africa currently number in the dozens.